Trial Profile
Study to assess the cognitive function as measured by NeuroTrax (NT) in patient with multiple sclerosis treated with natalizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 12 Oct 2018 Results (n=76) assessing Cognitive impairment as a predictor of therapeutic response to natalizumab, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 24 Aug 2018 Results published in the CNS Drugs